Bank of America’s Trillium Therapeutics Inc. TRIL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q4 | – | Sell |
-286,918
| Closed | -$5.04M | – | 9021 |
|
|
2021
Q3 | $5.04M | Buy |
286,918
+63,117
| +28% | +$737K | ﹤0.01% | 3557 |
|
|
2021
Q2 | $2.17M | Buy |
223,801
+38,945
| +21% | +$367K | ﹤0.01% | 4250 |
|
|
2021
Q1 | $1.99M | Sell |
184,856
-54,956
| -23% | -$680K | ﹤0.01% | 4267 |
|
|
2020
Q4 | $3.53M | Buy |
239,812
+107,712
| +82% | +$1.55M | ﹤0.01% | 3466 |
|
|
2020
Q3 | $1.88M | Sell |
132,100
-400
| -0.3% | -$3.99K | ﹤0.01% | 3729 |
|
|
2020
Q2 | $1.07M | Sell |
132,500
-43,542
| -25% | -$269K | ﹤0.01% | 4074 |
|
|
2020
Q1 | $711K | Buy |
176,042
+174,042
| +8,702% | +$658K | ﹤0.01% | 4256 |
|
|
2019
Q4 | $2K | Buy |
+2,000
| New | +$765 | ﹤0.01% | 6921 |
|
|
2019
Q3 | – | Sell |
-250
| Closed | – | – | 7635 |
|
|
2019
Q2 | $0 | Buy |
250
+150
| +150% | +$77 | ﹤0.01% | 7534 |
|
|
2019
Q1 | $0 | Sell |
100
-500
| -83% | -$611 | ﹤0.01% | 7545 |
|
|
2018
Q4 | $1K | Buy |
+600
| New | +$1.8K | ﹤0.01% | 7025 |
|
|
2018
Q3 | – | Sell |
-763
| Closed | -$5K | – | 7560 |
|
|
2018
Q2 | $5K | Buy |
+763
| New | +$4.86K | ﹤0.01% | 6809 |
|
|
2017
Q4 | – | Sell |
-400
| Closed | -$2K | – | 7362 |
|
|
2017
Q3 | $2K | Buy |
+400
| New | +$1.88K | ﹤0.01% | 6887 |
|
|
2017
Q2 | – | Sell |
-1,100
| Closed | -$7K | – | 7279 |
|
|
2017
Q1 | $7K | Sell |
1,100
-14,700
| -93% | -$86.2K | ﹤0.01% | 6622 |
|
|
2016
Q4 | $89K | Buy |
15,800
+15,400
| +3,850% | +$153K | ﹤0.01% | 5684 |
|
|
2016
Q3 | $6K | Buy |
400
+398
| +19,900% | +$4.58K | ﹤0.01% | 6569 |
|
|
2016
Q2 | $0 | Sell |
2
-798
| -100% | -$8.29K | ﹤0.01% | 7499 |
|
|
2016
Q1 | $7K | Buy |
800
+514
| +180% | +$4.33K | ﹤0.01% | 6502 |
|
|
2015
Q4 | $4K | Sell |
286
-21
| -7% | -$292 | ﹤0.01% | 6970 |
|
|
2015
Q3 | $4K | Buy |
+307
| New | +$5.64K | ﹤0.01% | 6852 |
|
Other funds holding TRIL
Bank of America's TRIL Position: Q4 2021 in Review
Bank of America sold out of Trillium Therapeutics Inc. (TRIL) in Q4 2021, closing a stake of 286,918 shares — an estimated $5.04M sold.
Bank of America first reported a position in TRIL in Q3 2015 and held it in 20 quarters. The position peaked at $5.04M in Q3 2021. 2 funds tracked by Wall St. Rank hold TRIL as of Q4 2021.
- Bank of America reported no remaining Trillium Therapeutics Inc. position as of Q4 2021 after selling out during the quarter.
- Bank of America sold 286,918 Trillium Therapeutics Inc. shares in Q4 2021, an estimated $5.04M.
- Bank of America first reported a position in Trillium Therapeutics Inc. in Q3 2015 and held it in 20 quarters.
- Bank of America's Trillium Therapeutics Inc. position peaked at $5.04M in Q3 2021.
- 2 funds tracked by Wall St. Rank held Trillium Therapeutics Inc. as of Q4 2021.
Based on Bank of America's 13F filing for Q4 2021, filed 8 Feb 2022.